Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.

Association of a poor response with concomitant topical use of steroids or vitamin D was of significance (OR = 0.12, 95% CI 0.03–0.53, p = 0.005), but that with severe disease status was of borderline significance (OR = 0.29, 95% CI 0.08–1.04, p = 0.058). 3.9 Drug survival and reasons for drug discontinuation The Kaplan–Meier curve of drug survival for patients with plaque psoriasis was almost the same as that for patients with psoriatic arthritis and drug survival rates after 1 year were approximately 60% (Figure 4a ).

also in 2,624 other papers